Interestingly, proteomic analysis of AD-mimetic brain organoids revealed that hallucinogens can attenuate Aβ plaque deposition and inhibit tau hyperphosphorylation by activating 5-HT2A receptors (Androni et al., 2025), making hallucinogens as promising drug candidates for treating AD. This evidence concerns the gene MAPT and Alzheimer disease.